obesity treatment with bariatric surgery vs glp-1 receptor agonists Metabolic and versus glucagon-like peptide-1 agonist therapy: A comparison of cardiovascular outcomes in patients Metabolic Bariatric Surgery vs. GLP-1

In: Joint Congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025, Copenhagen, Denmark: Endocrine Abstracts

KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Adverse Effects Aside from the debated increased risk of DR progression, a separate complication that has garnered widespread attention is the purported association of semaglutide with an increased risk of NAION, a vision-threatening condition

Further clinical trials and experience will help improve our understanding of the benefits of this drug

Impact of GLP-1 agonists on male reproductive healthA narrative review

PubMedPMC 62